 |
|
|
|
 |
|
|
| Article 1 to 10 out of 22 concerning MedImmune, Inc.
|
-
DIREVO to collaborate with MedImmune on therapeutic protease for the treatment of CNS diseases
(01/25/2008)
DIREVO Biotech AG announced the signing of a research and license agreement with MedImmune, the global biologics unit of AstraZeneca plc, to develop a therapeutic protease for the treatment of CNS diseases. Under the terms of the agreement, Direvo ...
-
MedImmune and Crucell jointly develop new antibodies for the treatment and prevention of hospital-acquired bacterial infection
(10/17/2007)
MedImmune and Crucell N.V. announced that they have entered into an exclusive license and research collaboration to further develop and commercialize one of Crucell's panels of bacterial antibodies primarily for the treatment and prevention of ...
-
MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
(08/28/2007)
New Facility Allows MedImmune to Meet Increasing Demands for Clinical Trial Materials from Company's Expanding and Advancing Pipeline
MedImmune unveiled a new, state-of-the-art pilot lab facility located on the same Gaithersburg site as its headquarters. With its cutting-edge equipment and process automation systems, the facility shall support MedImmune's expanding clinical ...
-
AstraZeneca to acquire MedImmune for $15.2 billion
(04/25/2007)
AstraZeneca PLC announced that it has entered into a definitive agreement to acquire MedImmune, Inc. in an all-cash transaction. Under the terms of the agreement, which has unanimous MedImmune Board support, AstraZeneca will acquire all of the fully ...
-
MedImmune Leases Human Genome Sciences Facility to Expand Cell Culture Influenza Vaccine Manufacturing Capabilities
(03/20/2007)
MedImmune, Inc. and Human Genome Sciences, Inc. (HGS) announced that they have signed an agreement under which MedImmune will lease a portion of an HGS facility located in Rockville, MD, for the development and manufacturing of clinical trial ...
-
MedImmune Completes Sale of CytoGam
(12/21/2006)
MedImmune, Inc. announced that it has completed its sale of CytoGam(R) (cytomegalovirus immune globulin intravenous (human)) to ZLB Behring. As specified in the agreement executed November 8, 2006, ZLB Behring has made a one-time upfront payment of ...
-
Infinity and MedImmune Announce Promising Biological Activity of Anti-Hsp90 Compound in Phase I GIST Trial
(11/09/2006)
Infinity Pharmaceuticals, Inc. and MedImmune, Inc. announced preliminary results from an open-label Phase I clinical study of IPI-504 in patients with GleevecŪ-resistant metastatic gastrointestinal stromal tumors (GIST). IPI-504, Infinity's lead ...
-
MedImmune and Infinity Pharmaceuticals Announce Cancer Drug Development and Worldwide Commercialization Agreement
(08/30/2006)
Alliance to Focus on Novel, Targeted Small Molecule Cancer Therapeutics in Two Key Programs
MedImmune, Inc. and Infinity Pharmaceuticals, Inc. announced that they have entered into an agreement to jointly develop and commercialize novel small molecule cancer drugs targeting Heat Shock Protein 90 (Hsp90) and the Hedgehog cell-signaling ...
-
MedImmune and National Institutes of Health Begin Clinical Testing of a Live, Attenuated Intranasal H5N1 Vaccine
(06/19/2006)
MedImmune, Inc. announced that the National Institutes of Health (NIH) has begun enrolling participants in a Phase 1 study of an intranasal H5N1 influenza vaccine candidate based on the company's live, attenuated vaccine technology. Investigators at ...
-
MedImmune Licenses Elusys Therapeutics' Technology for Use in Developing New Therapies Targeting Infectious Disease
(04/24/2006)
MedImmune, Inc. announced that it has entered into an exclusive licensing and collaboration agreement with privately held biopharmaceutical company Elusys Therapeutics, Inc. for select infectious disease targets. Under the agreement, MedImmune will ...
Additional information
MedImmune, Inc.
Gaithersburg, MD, United States of America
Company
|
|
|
|
|
|
Top
